An Observational Monocentric Study Investigating the Association Between Trough Serum Levels of Etanercept, Antibodies Towards Etanercept and Its Effectiveness in Psoriasis Patients

Intermittent Versus Continuous Treatment: an Observational Monocentric Study Investigating the Association Between Trough Levels of Enbrel and Therapy Regimen

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02322580

Acronym

DERM

Enrollment

Registered

2014-12-23

Start date

2015-01-31

Completion date

2016-11-30

Last updated

2016-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis

Keywords

anti-TNF, therapeutic drug monitoring, immunogenicity

Brief summary

The purpose of this study is to investigate the association between trough serum levels of etanercept, antibodies towards etanercept and its effectiveness in psoriasis patients.

Interventions

DRUGetanercept

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age from 18 years on, male or female * Established diagnosis of psoriasis * Etanercept either on monotherapy or in combination with acitretin (Neotigason®), given according to the current EU SmPC including the safety measures. * Patients who give informed consent for this study

Design outcomes

Primary

Measure	Time frame
anti-etanercept serum concentration	one year
trough serum etanercept concentration	one year

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026